title: "Sacubitril/Valsartan vs. Aliskiren: Two Trajectories of Cardiac Remodelling in Chronic Heart Failure"
description: "A 12-month comparative study finds sacubitril/valsartan drives early clinical improvement, while aliskiren produces slower but more pronounced structural reverse remodelling."
study_type: "Randomized controlled trial"
pubmed_id: "42922211"
journal: "La Clinica terapeutica"
In a 12-month comparison of two drugs for chronic heart failure, sacubitril/valsartan produced faster clinical improvement, while aliskiren produced greater structural recovery of the heart by 12 months. Evidence tier: (single trial, sample size not reported, limited publicly available detail).
This study compared two renin-angiotensin pathway agents, sacubitril/valsartan and aliskiren, in patients with chronic heart failure in Georgia over a 12-month follow-up. The authors were interested in whether the two therapies differ in how they affect cardiac remodelling, metabolic balance, neurohumoral activation, and symptom severity. The reported design is a randomized controlled trial, but the sample size is not stated in the available record, which limits how much weight the individual numbers can carry.
The sacubitril/valsartan group showed early improvement. By 6 months, systolic blood pressure fell by 6.2% (p<0.001), respiratory rate fell by 4.5% (p<0.001), N-terminal pro-B-type natriuretic peptide (NT-proBNP) fell by 10.0% (p<0.05), and oxygen saturation rose by 3.5% (p<0.001). Left ventricular ejection fraction (LVEF) rose from 34.2 ± 4.7% to 37.4 ± 4.0% at 6 months (p<0.001) and to 40.5 ± 3.5% at 12 months (p<0.001). By study end, 9.3% of patients in this group had reached New York Heart Association (NYHA) class I. Changes in NT-proBNP and LVEF are biomarker and imaging measures, not direct measures of how patients feel or function day to day, so the clinical meaning of the early gains should be read with that in mind.
The aliskiren group followed a different pattern. Reductions in left ventricular end-systolic volume (-15.8%, p=0.009), end-diastolic volume (-17.6%, p=0.016), and end-systolic diameter (p=0.002) appeared only at 12 months, alongside a modest rise in ejection fraction (p=0.030). The authors also report regression of functional mitral and tricuspid regurgitation and a 19.7% drop in pulmonary artery systolic pressure (p<0.05), with these structural changes described as more prominent in this group. The authors interpret this as slower but more pronounced reverse remodelling of the heart's structure.
Both groups showed improvements in metabolic markers, including reductions in glycated haemoglobin, low-density lipoprotein cholesterol, and triglycerides (p<0.05 for all). The authors describe this as a favourable systemic metabolic effect common to both therapies. Because the study compared two drugs with each other and did not include a no-treatment control, these metabolic changes cannot be attributed to either drug on their own relative to doing nothing.
Taken together, the authors conclude that sacubitril/valsartan may be preferable when rapid clinical stabilization is needed, while aliskiren may be a reasonable option for patients with advanced structural remodelling. This is a reasonable reading of the reported data, but it is a conclusion drawn from a single study with an unreported sample size, and it should be confirmed in larger, independently replicated trials before it shapes practice. The comparison also cannot tell us which drug improves long-term survival, since mortality is not the focus of the reported outcomes.
This study concerns prescription medications managed by a cardiologist, not supplements or lifestyle habits, so there are no product recommendations here. If you have chronic heart failure, the choice between these therapies is a clinical decision that depends on your specific heart function, symptoms, and other health conditions. Do not change or stop any prescribed medication based on this summary; discuss the findings with your treating clinician.
For readers interested in general heart health, the study's most consistent message is that metabolic markers such as blood sugar, LDL cholesterol, and triglycerides responded to treatment in both groups. Managing these markers is an established part of cardiovascular care, and your clinician can advise on how they apply to you.
| Field | Detail |
|---|---|
| Study type | Randomized controlled trial |
| Population | Patients with chronic heart failure, Georgia |
| Sample size | Not reported |
| Follow-up | 12 months |
| Interventions | Sacubitril/valsartan vs. aliskiren |
| Key outcomes | LVEF, NYHA class, NT-proBNP, LV volumes, mitral/tricuspid regurgitation, pulmonary artery pressure, glycated haemoglobin, LDL cholesterol, triglycerides |
| Journal | La Clinica terapeutica |
| PubMed ID | 42922211 |
| Evidence tier |
1. Myocardial remodelling during sacubitril/valsartan therapy in patients with chronic heart failure. *La Clinica terapeutica*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42922211/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.